ClinicaliQ Trial Snapshot
- HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) — Active Not Recruiting • Phase II • Diabetes / Metabolic • NCT04732416.
- Eight-week study testing weekly injections of HM15136 as add-on treatment for children with congenital hyperinsulinism who remain hypoglycaemic.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data. Conditions: Congenital Hyperinsulinism Interventions: HM15136 Lead Sponsor: Hanmi Pharmaceutical Company Limited Planned Enrollment: 17 participants